Skip to search formSkip to main contentSkip to account menu

Maxzide

National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

HydrochlorothiazideTriamterenehydrochlorothiazide-triamterene

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
A Comparison of the Anti‐Hypertensive Effectiveness of Two Triameterene/Hydrochlorothiazide Combinations: Maxzide Versus Dyazide
The hydrochlorothiazide component of Maxzide (Lederle Laboratories, Pearl River, NY) has been shown to be more bioavailable than… 
1988
1988
The PACT Study: Post-Marketing Surveillance in 47,465 Patients Treated with Maxzide
1987
1987
Serum magnesium and potassium levels in hypertensive patients after a therapeutic switch from hydrochlorothiazide plus a potassium supplement to maxzide.
1986
1986
The PACT study: post-marketing surveillance in 47,465 patients treated with Maxzide (triamterene/hydrochlorothiazide). An interim report.
1985
1985
Maxzide or Dyazide: a cautionary note.
Excerpt To the editor: A massive campaign, including eight-page, heavy-paper advertisements in most medical journals, has been… 
1984
1984
A new antihypertensive agent: Maxzide (75 mg triamterene/50 mg hydrochlorothiazide).
1984
1984
Bioequivalence study of a new tablet formulation of triamterene and hydrochlorothiazide.
1984
1984
Clinical experience with a new combination formulation of triamterene and hydrochlorothiazide (Maxzide) in patients with mild to moderate hypertension.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)